Insulin pricing in flux as major pharma players take action
As the three main US pharmaceutical insulin suppliers, Novo Nordisk, Sanofi and Eli Lilly, have announced major price reductions, and…
Pharma Pricing Strategy
-
-
Risk sharing agreements soar as market access risk increases
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said…
-
Sanofi offers refunds for Cablivi in novel model for rebates
On January 18, Sanofi launched a new warranty program for its rare blood disorder drug Cablivi (caplacizumab), which tackles value-based…
-
Will IRP upend Czech orphan drug reforms?
On 14 September, the Czech Chamber of Deputies gave its final approval to the amendment of the Public Health Insurance…
-
Variations on an IRP theme: How payers are repurposing pricing policies for new categories of medicines
"Don't reinvent the wheel." "If it ain't broke, don't fix it." These are adages as old as time. And they…
-
California’s Medicaid pharmacy “carve-out” set to boost state’s negotiating power, introduce IRP for drugs
California is planning a major overhaul of its Medicaid Pharmacy benefit, called Medi-Cal Rx, that will result in a "carve-out"…
-
Trend towards HTA collaboration boosts need for data
The rising popularity of health technology assessments (HTAs) and similar framework agreements is presenting new challenges for the pharmaceutical industry.…
-
ESG permeates pharmaceutical pricing strategy
As ESG criteria gains greater traction across the pharmaceutical landscape, the push for pricing sustainability is growing more forceful. To…
-
Germany’s ESG Law: A case study for new pharma pricing model
Pharmaceutical pricing is increasingly becoming a broader topic in the global push towards sustainability and environmental, social, and government (ESG)…
-
Canada’s PMPRB reform delays add uncertainty
The government of Canada has once again decided to delay the implementation of the major drug pricing reforms that were…
